Oscar Figueroa, MD
Pulmonary Disease · Wytheville, VANPI 1801889720
Payments from drug & device makers
Across 337 payments — averaging $22.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus Corporation Of The Americas$2K
- Boehringer Ingelheim$1K
- AstraZeneca$1K
- GSK$915
- Mylan Specialty L.p.$790
- Mallinckrodt Hospital Products Inc.$536
- plus $1K from 21 others
What the payments were for
- Travel & lodging$1,58721%
- Food & beverage$5,46472%
- Education$5838%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus Corporation Of The Americas | 15 | $1,694 |
| Boehringer Ingelheim | 78 | $1,140 |
| AstraZeneca | 44 | $1,108 |
| GSK | 64 | $915 |
| Mylan Specialty L.p. | 47 | $790 |
| Mallinckrodt Hospital Products Inc. | 28 | $536 |
| Vanda Pharmaceuticals Inc. | 8 | $188 |
| Genentech USA, Inc. | 4 | $183 |
| Regeneron Healthcare Solutions, Inc. | 10 | $182 |
| Sanofi-aventis U.S. LLC | 2 | $180 |
| Harmony Biosciences LLC | 4 | $111 |
| Sanofi | 6 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $98 |
| CSL Behring | 4 | $86 |
| Axsome Therapeutics, Inc. | 3 | $50 |
| Amgen | 2 | $35 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Baxter Healthcare | 2 | $30 |
| Electromed, Inc. | 1 | $26 |
| Tactile Systems Technology Inc | 1 | $23 |
| Lilly USA, LLC | 1 | $21 |
| Inogen, Inc. | 1 | $21 |
| Apria Healthcare LLC | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Verona Pharma, Inc. | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
| Viatris Specialty LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SINGLE USE SUCTION VALVE (Sterile)$1,290
- TEZSPIRE$335
- FASENRA$210
- AIRSUPRA$107
- BREZTRI$103
How this compares
$7,634 in reported general payments places this provider in the 65th percentile of 317 pulmonary disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 404 | $331,485 |
| UptraviSelexipag | 11 | $237,886 |
| OfevNintedanib Esylate | 11 | $145,819 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 155 | $128,635 |
| Spiriva RespimatTiotropium Bromide | 60 | $44,420 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 73 | $40,014 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 61 | $37,918 |
| SymbicortBudesonide/Formoterol Fumarate | 88 | $30,303 |
| Breo ElliptaFluticasone/Vilanterol | 55 | $24,872 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 31 | $15,364 |
| Spiriva HandihalerTiotropium Bromide | 22 | $13,035 |
| Theophylline ErTheophylline Anhydrous | 132 | $10,344 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 266 | $8,137 |
| Varenicline Tartrate | 26 | $7,503 |
| Atrovent HfaIpratropium Bromide | 15 | $6,947 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $915 | $400,183543 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $1,140 | $243,521163 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi | $15 | $237,88611 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,108 | $158,939243 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 317 pulmonary disease providers in Virginia.
Other pulmonary disease in Wytheville
- Steven NathanFalls Church$2.5M
- Shilpa JohriRichmond$1.7M
- Omar MinaiHopewell$1.3M
- Vijay SubramaniamWilliamsburg$1.3M
- Rabih HalabiFalls Church$604K
- Patricia SimeRichmond$572K
- Apostolos PerelasRichmond$567K
- Hannah MannemCharlottesville$326K
- Ray ShepherdRichmond$303K
- Eric LibreAnnandale$302K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.